Eduardo
Castañón Álvarez
Consultor Médico
Gustave Roussy Cancer Campus
Villejuif, FranciaPublicacions en col·laboració amb investigadors/es de Gustave Roussy Cancer Campus (13)
2022
-
Genome-driven medicine for patients with recurrent glioma enrolled in early phase trials
European Journal of Cancer, Vol. 163, pp. 98-107
2021
-
Association of the lung immune prognostic index with immunotherapy outcomes in mismatch repair deficient tumors
Cancers, Vol. 13, Núm. 15
-
Intratumoural administration and tumour tissue targeting of cancer immunotherapies
Nature Reviews Clinical Oncology, Vol. 18, Núm. 9, pp. 558-576
-
Patterns of progression in patients treated for immuno-oncology antibodies combination
Cancer Immunology, Immunotherapy, Vol. 70, Núm. 1, pp. 221-232
2020
-
Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types
Cancer Medicine, Vol. 9, Núm. 8, pp. 2643-2652
2019
-
Met receptor amplification drives resistance to anti-egfr therapies
Journal of Immunotherapy and Precision Oncology, Vol. 2, Núm. 4, pp. 152-155
2018
-
Are phase I trials safe for older patients?
Journal of Geriatric Oncology, Vol. 9, Núm. 2, pp. 87-92
-
Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours
European Journal of Cancer, Vol. 95, pp. 68-74
-
Locally advanced cervical cancer with bladder invasion: Clinical outcomes and predictive factors for vesicovaginal fistulae
Oncotarget, Vol. 9, Núm. 10, pp. 9299-9310
2017
-
3D waterfall plots: A better graphical representation of tumor response in oncology
Annals of Oncology
-
Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)
European Journal of Cancer, Vol. 84, pp. 202-211
-
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)
European Journal of Cancer, Vol. 84, pp. 212-218
2016
-
Anti-PD1-induced pneumonitis: Capturing the hidden enemy
Clinical Cancer Research, Vol. 22, Núm. 24, pp. 5956-5958